PVCT News and Press, Provectus Biopharmaceuticals Inc From 12/12/19

13 patients treated to date have received single-agent PV-10 or combination of PV-10 and standard of care checkpoint blockade Independent safety profiles of PV-10 and checkpoint inhibition were maintained 32% ORR and 82% DCR of injected visceral hepatic target lesions (2D EASL) KNOXVI...

Noteworthy events during the week of December 8 - 14 for healthcare investors. More news on: Roche Holding AG, Athenex, Inc., Anixa Biosciences, Inc., Healthcare stocks news, , Read more ...

KNOXVILLE, TN, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of lysosomal-targeting cancer immunotherapy PV-10 (rose bengal disodium) as a single-agent for the treatment of primary or metastatic tumors of the liver ( NCT0...

First 10 checkpoint-refractory melanoma patients treated Established safety profiles of PV-10 and KEYTRUDA were maintained 20% ORR and 40% DCR (RECIST 1.1) Changes in immune system activation biomarkers of checkpoint-refractory patients were similar to those of single-agent PV-10- and P...

Full accrual of 21 checkpoint-naïve melanoma patients No safety concerns identified; no significant overlap of toxicities 95% 12-month OS rate; 100% 12-month DSS rate; Median PFS of 11.7 months 10% CR and 67% ORR (RECIST 1.1) overall; 82% ORR for Stage M1b-c KNOXVILLE, TN, Nov....

KNOXVILLE, TN, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of lysosomal-targeting, cancer immunotherapy PV-10 (rose bengal disodium) as a single-agent and in combination with standard of care checkpoint inhibition for th...

KNOXVILLE, TN, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of lysosomal-targeting cancer immunotherapy PV-10 ® in combination with checkpoint inhibition for the treatment of advanced cutaneous melanoma ( NCT02557...

Dr. Schmitz, General Partner of The March Fund and former Chief Science Officer of Mars, Incorporated is Provectus’ inaugural Scientific Advisory Board member KNOXVILLE, TN, Sept. 11, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced the addition of Dr. Harold Sch...

Two-stage, 34-patient, Phase 2 study combines PV-10 and Keytruda ® (pembrolizumab) for treatment of metastatic neuroendocrine tumors Combination powered for 19% ORR vs 3.7% ORR for Keytruda (KEYNOTE-158) Interim assessment conducted 24 weeks after initial treatment of 9 th patien...

Dr. Akers to assist Provectus develop and manage new Company scientific advisory board KNOXVILLE, TN, July 29, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced the addition of Dr. Frank Akers to the Company’s Strategic Advisory Board (“SAB”), effecti...